Ligand Pharmaceuticals Incorporated : The underlying trend is to the upside
Entry price | Target | Stop-loss | Potential |
---|
$156.22 |
$171 |
$149.9 |
+9.46% |
---|
Ligand Pharmaceuticals Inc. shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths● Share prices are approaching a strong support area in daily data, which offers good timing for investors.
● The prospective high growth for the next fiscal years is among the main assets of the company
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
● For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
● Within the weekly time frame the stock shows a bullish technical configuration above the support level at 140.31 USD
Weaknesses● With an expected P/E ratio at 44.16 and 38.99 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.